Functional consequences of ITPase deficiency and the impact of inosine misincorporation into the transcriptome
- Institution
- STATE UNIVERSITY OF NEW YORK AT ALBANY, NY
- Principal investigator
- Kaalak Reddy
- Funding
- $423K
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
Project Abstract Bi-allelic loss of function variants in the ITPA gene cause a fatal infantile multisystem developmental disorder characterized by epileptic encephalopathy and dilated cardiomyopathy. ITPA encodes the inosine triphosphate pyrophosphatase (ITPase) enzyme which hydrolyzes inosine triphosphate (ITP) and deoxyITP to prevent their accumulation in cellular nucleotide pools and subsequent misincorporation during RNA and DNA synthesis. Although the biochemical activity of ITPase is well understood, the molecular and cellular mechanisms underlying the pathology resulting from ITPase deficiency are unknown. ITPase-deficient patient cells, mouse embryonic stem cells and tissues contain high levels of misincorporated inosine within bulk RNA but deoxyinosine is undetectable within DNA, due to active DNA repair processes. To investigate the functional consequences of ITPase deficiency and inosine misincorporation into the transcriptome; Aim 1) Illumina RNA sequencing (RNA-seq) and Oxford Nanopore Long-Read sequencing will be performed on CRISPR/Cas9-derived ITPA-null human induced pluripotent stem cells (iPSCs), pre- and post-differentiation into neurons and cardiomyocytes to evaluate transcriptome deregulation (transcript abundance, splicing and polyadenylation) and novel transcript isoforms. In parallel, inosine accumulation as a direct driver of transcriptome dysregulation will be tested by culturing ITPA-null cells with inosine nucleoside in the culture media. The resulting inosine misincorporation into total RNA will be measured using mass spectrometry prior to RNA-seq and long read sequencing. Aim 2) The impact of ITPase deficiency and inosine misincorporation into RNA on translation will be determined. Ribosome profiling (Ribo-Seq) of ITPA-null neurons and cardiomyocytes will be performed under basal and inosine nucleoside treatment conditions to determine translation efficiency and to pinpoint mRNA targets of altered translation. Inosine misincorporation into rRNA, tRNA and mRNA will be quantified using mass spectrometry and potential activation of cellular stress markers will be investigated. The proposed work will identify transcriptome and translation alterations resulting from ITPase deficiency. The findings of this research will aid in elucidating the unknown pathogenic mechanism(s) underlying ITPase-deficiency and may reveal novel therapeutic targets for treating this rare but fatal disorder. The impact of this work extends to other disorders of nucleotide pool maintenance and may shed new light on our understanding of inosine in A-to-I RNA editing and gene expression during development and disease from a unique perspective.
Research team
- Gabriele FuchsPI
- Kaalak ReddyPI
LOADING MOONBASE SCORE
Questions for STATE UNIVERSITY OF NEW YORK AT ALBANY
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · State University of New York at Albany54
N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy
Bijan K Dey · $200K · 2023–2026
- NIH · State University of New York at Albany52
Animal testing of RNA aptamers as ALS drug candidate
Li Niu · $364K · 2022–2026
- NIH · State University of New York at Albany48
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias
Andrew Berglund · $574K · 2023–2028